Thalia Therapeutics (THAT) Stock Overview
A specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
THAT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Thalia Therapeutics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0063 |
| 52 Week High | UK£0.01 |
| 52 Week Low | UK£0.0035 |
| Beta | 0.52 |
| 1 Month Change | 31.58% |
| 3 Month Change | 31.58% |
| 1 Year Change | 66.67% |
| 3 Year Change | -69.51% |
| 5 Year Change | -92.42% |
| Change since IPO | -90.20% |
Recent News & Updates
Recent updates
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth
Oct 11
Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Jul 06Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth
Dec 07
Shareholder Returns
| THAT | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 38.9% | -1.4% | 1.7% |
| 1Y | 66.7% | 40.9% | 29.5% |
Return vs Industry: THAT exceeded the UK Pharmaceuticals industry which returned 40.9% over the past year.
Return vs Market: THAT exceeded the UK Market which returned 29.5% over the past year.
Price Volatility
| THAT volatility | |
|---|---|
| THAT Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: THAT's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: THAT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 4 | David Solomon | www.thaliatx.com |
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring.
Thalia Therapeutics Plc Fundamentals Summary
| THAT fundamental statistics | |
|---|---|
| Market cap | UK£5.62m |
| Earnings (TTM) | -UK£1.10m |
| Revenue (TTM) | UK£7.07k |
Is THAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THAT income statement (TTM) | |
|---|---|
| Revenue | UK£7.07k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£7.07k |
| Other Expenses | UK£1.11m |
| Earnings | -UK£1.10m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15,600.13% |
| Debt/Equity Ratio | 0% |
How did THAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 17:50 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Thalia Therapeutics Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emma Ulker | Allenby Capital Limited |